IP and IP analogs dosage regimens for the treatment of ectopic calcifications
The present disclosure related to compositions, methods, dosages, dosage regimens, articles of manufacture and kits for the treatment and/or prevention ectopic calcifications, and in particular cutaneous calcifications such as calciphylaxis calcifications comprising inositol phosphate, inositol phosphate analogs, inositol phosphate derivatives, or combinations thereof. In a particular aspect the disclosure provides a dosage regimen to treat calciphylaxis comprising the administration of 6 mg/kg to 9 mg/kg daily doses of myo-inositol hexaphosphate, three times a week, for at least 1 to 8 months.
1. A method to treat or inhibit the occurrence of calciphylaxis calcification and/or the consequences thereof in a subject in need thereof comprising administering an intravenous dose of inositol hexaphosphate, in a dosage of about 5 mg to 10 mg of inositol hexaphosphate per kg per day to the subject wherein the administration of the dosage effectively treats or inhibit the occurrence of calciphylaxis calcification and/or the consequences thereof in the subject.
2. The method of claim 1 , wherein the inositol hexaphosphate is myo-inositol hexaphosphate.
3. The method of claim 1 , wherein the inositol hexaphosphate is a sodium salt.
4. The method of claim 3 , wherein the inositol hexaphosphate is SNF472 (hexasodium salt of myo-inositol hexaphosphate).
5. The method of claim 1 , wherein the dosage is about 6 mg per kg to about 9 mg of inositol hexaphosphate per kg.
6. The method of claim 5 , wherein the dosage is about 7 mg of inositol hexaphosphate per kg.
7. The method of claim 1 , wherein the dosage comprises a dose of about 300 mg to about 600 mg of inositol hexaphosphate.
8. The method of claim 7 , wherein the dosage comprises a dose of about 450 mg of inositol hexaphosphate.
9. The method of claim 1 , wherein the dosage is administered as a single daily dose or as multiple daily doses.
10. The method of claim 1 , wherein the dosage is administered between 2 times and 7 times per week.
11. The method of claim 10 , wherein the dosage is administered 3 times per week.
12. The method of claim 1 , wherein the dosage is administered between 2 weeks and 32 weeks.
13. The method of claim 12 , wherein the dosage is administered for 12 weeks.
14. The method of claim 1 , wherein there administration of the dosage effectively treats calciphylaxis calcification and/or the consequences thereof in the subject by:
(i) reducing lesions as determined by the Bates-Jensen Wound Assessment tool;
(ii) improving lesion healing;
(iii) reducing pain;
(iv) improving global wound quality of life (QoL) as determined by using a validated wound-associated QoL questionnaire; or,
(v) a combination thereof.
15. The method of claim 14 , wherein reducing lesions comprises a reduction in the severity of the lesions, a reduction in the size of the lesions, and reduction in the duration of the lesions, or a combination thereof.
16. The method of claim 1 , wherein the consequence of the calciphylaxis calcification is a functional complication, pain, a trophic complication, an infection, or a combination thereof.
17. The method of claim 16 , wherein the function complication is a limitation of range of motion and/or joint function.
18. The method of claim 16 , wherein the trophic complication is ischemia and/or a lesion.
19. The method of claim 18 , wherein the lesion is necrosis of the cutaneous and/or subcutaneous tissues.
20. The method of claim 1 , wherein the subject has end-stage renal disease and/or is on hemodialysis.
21. The method of claim 1 , wherein the intravenous administration is by bolus injection or by infusion.
22. The method of claim 1 , wherein the administration of the dosage to the subject inhibits the formation and/or growth of hydroxyapatite crystals.
23. A method to treat or inhibit the occurrence of calciphylaxis calcification and/or the consequences thereof in a subject in need thereof comprising administering an intravenous dose of inositol hexaphosphate, in a dosage of about 7 mg of inositol hexaphosphate per kg per day to the subject wherein the administration of the dosage effectively treats or inhibits the occurrence of calciphylaxis calcification and/or the consequences thereof in the subject.
24. The method of claim 23 , wherein the inositol hexaphosphate is myo-inositol hexaphosphate.
25. The method of claim 23 , wherein the inositol hexaphosphate is a sodium salt.
26. The method of claim 23 , wherein the inositol hexaphosphate is SNF472 (hexasodium salt of myo-inositol hexaphosphate).
27. The method of claim 23 , wherein the dosage is administered 2, 3, 4, 5, 6, or 7 days per week.
28. The method of claim 27 , wherein the dosage is administered 3 days per week.
29. The method of claim 23 , wherein the dosage is administered for about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 or 32 weeks.
30. The method of claim 29 , wherein the dosage is administered for 12 weeks.
31. The method of claim 23 , wherein the dosage is administered 3 days per week for 12 weeks.
32. A method to treat or inhibit the occurrence calciphylaxis calcification and/or the consequences thereof in a subject in need thereof comprising administering an intravenous dose of inositol hexaphosphate 3 days per week for 12 weeks in a dosage of about 7 mg of inositol hexaphosphate per kg per day to the subject, wherein the administration of the dosage effectively treats or inhibits the occurrence of calciphylaxis calcification and/or the consequences thereof in the subject.
33. The method of claim 32 , wherein the inositol hexaphosphate is myo-inositol hexaphosphate.
34. The method of claim 32 , wherein the inositol hexaphosphate is a sodium salt.
35. The method of claim 32 , wherein the inositol hexaphosphate is SNF472 (hexasodium salt of myo-inositol hexaphosphate).